Nuvectis Pharma, Inc. (NVCT)

NASDAQ: NVCT · IEX Real-Time Price · USD
7.09
-0.27 (-3.67%)
At close: Sep 30, 2022 4:00 PM
7.02
-0.07 (-0.99%)
After-hours: Sep 30, 2022 7:58 PM EDT
-3.67%
Market Cap 103.82M
Revenue (ttm) n/a
Net Income (ttm) -13.44M
Shares Out 14.64M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,820
Open 7.40
Previous Close 7.36
Day's Range 7.09 - 7.47
52-Week Range 3.08 - 20.92
Beta n/a
Analysts Buy
Price Target 21.08 (+197.3%)
Earnings Date Aug 9, 2022

About NVCT

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. [Read more...]

Industry Biotechnology
IPO Date Feb 4, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NVCT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for NVCT stock is "Buy." The 12-month stock price forecast is 21.08, which is an increase of 197.32% from the latest price.

Price Target
$21.08
(197.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of ...

3 days ago - GlobeNewsWire

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatme...

2 weeks ago - GlobeNewsWire

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatme...

3 weeks ago - GlobeNewsWire

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

FORT LEE, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of novel therapies for the tre...

1 month ago - GlobeNewsWire

Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicin...

2 months ago - GlobeNewsWire

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment...

3 months ago - GlobeNewsWire

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain...

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatmen...

3 months ago - GlobeNewsWire

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment o...

4 months ago - GlobeNewsWire

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing

4 months ago - GlobeNewsWire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research...

Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for ser...

5 months ago - GlobeNewsWire

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (...

Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for ser...

5 months ago - GlobeNewsWire

Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights

Complet ed Initial Public Offering in February 202 2 , R aising $16.0 million in G ross P roceeds

6 months ago - GlobeNewsWire

Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting

Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for ser...

6 months ago - GlobeNewsWire

Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in o...

6 months ago - GlobeNewsWire

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

Other symbols: CSIINOTV
7 months ago - InvestorPlace

Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Link...

Data Published in Cancer Research, a journal of the American Association for Cancer Research

7 months ago - GlobeNewsWire

Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock

New York, NY, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for the t...

7 months ago - GlobeNewsWire

NVCT Stock Alert: 7 Things to Know as Nuvectis Pharma Soars 200%

Here are a few things that investors in Nuvectis may want to know today, as NVCT stock surges on incredible volume. The post NVCT Stock Alert: 7 Things to Know as Nuvectis Pharma Soars 200% appeared fir...

7 months ago - InvestorPlace

Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock

Fort Lee, NJ, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicin...

7 months ago - GlobeNewsWire

Nuvectis Pharma Delays Listing as IPO Market Turns Cautious

Biotech company Nuvectis had planned to offer 2.3 million shares at $12 to $14 each.

10 months ago - Barrons

Nuvectis Pharma expected to be sole IPO in U.S. market this week

The U.S. initial public offering market is expected to see just one deal this week, taking a pause after the shortened holiday week. Last week, there was just one IPO and six SPACs, or special purpose a...

10 months ago - Market Watch

This Week's Scheduled IPOs

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are sch...

10 months ago - Benzinga